ICON'S Firecrest Training Recognized by TransCelerate
ICON announced that TransCelerate has certified its Firecrest GCP training as mutually acceptable for its members.
ICON announced that TransCelerate has certified that its Firecrest GCP training is mutually acceptable for its members. Under this TransCelerate initiative, investigators completing the training will avoid having to repeatedly complete pre-qualification GCP training for every trial. According to ICON, its Firecrest training has some features not available in other training programs, which include the ability for sponsors to assign training requirements per specific job role; track training compliance and notify users of overdue training or re-certification due dates; and enhanced reporting capabilities to analyze and report completion metrics at a region, site or role level.
Read the full release here.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
